

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Supplementary Appendix

Fig. S1. Estimates of TFS and other health states over the 36-month period in patient subgroups based on (a) ECOG performance status and (b) sex in patients treated with nivolumab plus ipilimumab. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; TFS, treatment-free survival.




Fig S2. Estimates of TFS and other health states over the 36-month period in patient subgroups based on (a) ECOG performance status and (b) sex in patients treated with nivolumab. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; TFS, treatment-free survival.




Fig. S3. Estimates of TFS and other health states over the 36-month period in patient subgroups based on (a) ECOG performance status and (b) sex in patients treated with ipilimumab. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; TFS, treatment-free survival.

